ID   DNMT1_MOUSE             Reviewed;        1620 AA.
AC   P13864; P97413; Q80ZU3; Q9CSC6; Q9QXX6;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2002, sequence version 5.
DT   18-JUN-2025, entry version 247.
DE   RecName: Full=DNA (cytosine-5)-methyltransferase 1;
DE            Short=Dnmt1;
DE            Short=Met-1;
DE            EC=2.1.1.37;
DE   AltName: Full=DNA methyltransferase MmuI;
DE            Short=DNA MTase MmuI;
DE            Short=M.MmuI;
DE   AltName: Full=MCMT;
GN   Name=Dnmt1; Synonyms=Dnmt, Met1, Uim;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3210246; DOI=10.1016/0022-2836(88)90122-2;
RA   Bestor T.H., Laudano A., Mattaliano R., Ingram V.;
RT   "Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse
RT   cells. The carboxyl-terminal domain of the mammalian enzymes is related to
RT   bacterial restriction methyltransferases.";
RL   J. Mol. Biol. 203:971-983(1988).
RN   [2]
RP   SEQUENCE REVISION TO N-TERMINUS.
RC   TISSUE=Embryo;
RX   PubMed=8940105; DOI=10.1074/jbc.271.49.31092;
RA   Yoder J.A., Yen R.-W.C., Vertino P.M., Bestor T.H., Baylin S.B.;
RT   "New 5' regions of the murine and human genes for DNA (cytosine-5)-
RT   methyltransferase.";
RL   J. Biol. Chem. 271:31092-31097(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   STRAIN=C57BL/6J; TISSUE=Skeletal muscle;
RX   PubMed=11063128;
RA   Aguirre-Arteta A.M., Grunewald I., Cardoso M.C., Leonhardt H.;
RT   "Expression of an alternative Dnmt1 isoform during muscle
RT   differentiation.";
RL   Cell Growth Differ. 11:551-559(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6J;
RX   PubMed=10715201; DOI=10.1006/jmbi.2000.3588;
RA   Margot J.B., Aguirre-Arteta A.M., Di Giacco B.V., Pradhan S., Roberts R.J.,
RA   Cardoso M.C., Leonhardt H.;
RT   "Structure and function of the mouse DNA methyltransferase gene: Dnmt1
RT   shows a tripartite structure.";
RL   J. Mol. Biol. 297:293-300(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-27 AND 119-1619 (ISOFORMS 1
RP   AND 2).
RX   PubMed=9449671; DOI=10.1242/dev.125.5.889;
RA   Mertineit C., Yoder J.A., Taketo T., Laird D.W., Trasler J.M., Bestor T.H.;
RT   "Sex-specific exons control DNA methyltransferase in mammalian germ
RT   cells.";
RL   Development 125:889-897(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 1-144 (ISOFORMS 1 AND 2), AND PROTEIN SEQUENCE OF
RP   3-6.
RC   STRAIN=129/Sv, and BALB/cJ; TISSUE=Embryonic stem cell;
RX   PubMed=9830015; DOI=10.1074/jbc.273.49.32725;
RA   Gaudet F., Talbot D., Leonhardt H., Jaenisch R.;
RT   "A short DNA methyltransferase isoform restores methylation in vivo.";
RL   J. Biol. Chem. 273:32725-32729(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-119 (ISOFORM 1).
RC   STRAIN=129/Sv; TISSUE=Embryonic stem cell, and Kidney;
RX   PubMed=8917520; DOI=10.1073/pnas.93.23.12920;
RA   Tucker K.L., Talbot D., Lee M.A., Leonhardt H., Jaenisch R.;
RT   "Complementation of methylation deficiency in embryonic stem cells by a DNA
RT   methyltransferase minigene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:12920-12925(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-272 (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [10]
RP   PROTEIN SEQUENCE OF 1108-1154, AND ACTIVITY REGULATION.
RX   PubMed=1628623; DOI=10.1002/j.1460-2075.1992.tb05326.x;
RA   Bestor T.H.;
RT   "Activation of mammalian DNA methyltransferase by cleavage of a Zn binding
RT   regulatory domain.";
RL   EMBO J. 11:2611-2617(1992).
RN   [11]
RP   PHOSPHORYLATION AT SER-515, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Erythroleukemia;
RX   PubMed=9211941; DOI=10.1074/jbc.272.28.17851;
RA   Glickman J.F., Pavlovich J.G., Reich N.O.;
RT   "Peptide mapping of the murine DNA methyltransferase reveals a major
RT   phosphorylation site and the start of translation.";
RL   J. Biol. Chem. 272:17851-17857(1997).
RN   [12]
RP   INTERACTION WITH HDAC1.
RX   PubMed=10615135; DOI=10.1038/71750;
RA   Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T.;
RT   "DNA methyltransferase Dnmt1 associates with histone deacetylase
RT   activity.";
RL   Nat. Genet. 24:88-91(2000).
RN   [13]
RP   INTERACTION WITH HDAC2 AND DMAP1.
RX   PubMed=10888872; DOI=10.1038/77023;
RA   Rountree M.R., Bachman K.E., Baylin S.B.;
RT   "DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at
RT   replication foci.";
RL   Nat. Genet. 25:269-277(2000).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11290321; DOI=10.1016/s0092-8674(01)00280-x;
RA   Howell C.Y., Bestor T.H., Ding F., Latham K.E., Mertineit C., Trasler J.M.,
RA   Chaillet J.R.;
RT   "Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1
RT   gene.";
RL   Cell 104:829-838(2001).
RN   [15]
RP   ALLOSTERIC REGULATION.
RX   PubMed=11399088; DOI=10.1006/jmbi.2001.4709;
RA   Fatemi M., Hermann A., Pradhan S., Jeltsch A.;
RT   "The activity of the murine DNA methyltransferase Dnmt1 is controlled by
RT   interaction of the catalytic domain with the N-terminal part of the enzyme
RT   leading to an allosteric activation of the enzyme after binding to
RT   methylated DNA.";
RL   J. Mol. Biol. 309:1189-1199(2001).
RN   [16]
RP   FUNCTION.
RX   PubMed=15550930; DOI=10.1038/sj.embor.7400295;
RA   Easwaran H.P., Schermelleh L., Leonhardt H., Cardoso M.C.;
RT   "Replication-independent chromatin loading of Dnmt1 during G2 and M
RT   phases.";
RL   EMBO Rep. 5:1181-1186(2004).
RN   [17]
RP   INTERACTION WITH BAZ2A.
RX   PubMed=16085498; DOI=10.1016/j.cub.2005.06.057;
RA   Zhou Y., Grummt I.;
RT   "The PHD finger/bromodomain of NoRC interacts with acetylated histone H4K16
RT   and is sufficient for rDNA silencing.";
RL   Curr. Biol. 15:1434-1438(2005).
RN   [18]
RP   INTERACTION WITH THE PRC2 COMPLEX.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [19]
RP   ERRATUM OF PUBMED:16357870.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [20]
RP   PHOSPHORYLATION AT SER-515, AND MUTAGENESIS OF SER-515.
RX   PubMed=17965600; DOI=10.4161/epi.2.3.4768;
RA   Goyal R., Rathert P., Laser H., Gowher H., Jeltsch A.;
RT   "Phosphorylation of serine-515 activates the mammalian maintenance
RT   methyltransferase Dnmt1.";
RL   Epigenetics 2:155-160(2007).
RN   [21]
RP   FUNCTION, MUTAGENESIS OF GLN-162; PHE-169 AND CYS-1229, AND ACTIVE SITE.
RX   PubMed=17576694; DOI=10.1093/nar/gkm432;
RA   Schermelleh L., Haemmer A., Spada F., Roesing N., Meilinger D.,
RA   Rothbauer U., Cardoso M.C., Leonhardt H.;
RT   "Dynamics of Dnmt1 interaction with the replication machinery and its role
RT   in postreplicative maintenance of DNA methylation.";
RL   Nucleic Acids Res. 35:4301-4312(2007).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152 AND SER-717, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-717, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-15; SER-138; SER-140;
RP   SER-146; SER-150; SER-152; SER-240; SER-713 AND SER-717, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [25]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP7, AND INTERACTION WITH USP7 AND
RP   UHRF1.
RX   PubMed=21268065; DOI=10.1002/jcb.22998;
RA   Qin W., Leonhardt H., Spada F.;
RT   "Usp7 and Uhrf1 control ubiquitination and stability of the maintenance DNA
RT   methyltransferase Dnmt1.";
RL   J. Cell. Biochem. 112:439-444(2011).
RN   [26]
RP   PHOSPHORYLATION AT SER-146 BY CSNK1D/CK1, AND INTERACTION WITH CSNK1D.
RX   PubMed=20192920; DOI=10.1042/bj20091856;
RA   Sugiyama Y., Hatano N., Sueyoshi N., Suetake I., Tajima S., Kinoshita E.,
RA   Kinoshita-Kikuta E., Koike T., Kameshita I.;
RT   "The DNA-binding activity of mouse DNA methyltransferase 1 is regulated by
RT   phosphorylation with casein kinase 1delta/epsilon.";
RL   Biochem. J. 427:489-497(2010).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1122 AND LYS-1124, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=23806337; DOI=10.1016/j.molcel.2013.06.001;
RA   Park J., Chen Y., Tishkoff D.X., Peng C., Tan M., Dai L., Xie Z., Zhang Y.,
RA   Zwaans B.M., Skinner M.E., Lombard D.B., Zhao Y.;
RT   "SIRT5-mediated lysine desuccinylation impacts diverse metabolic
RT   pathways.";
RL   Mol. Cell 50:919-930(2013).
RN   [28]
RP   INTERACTION WITH SIRT7.
RX   PubMed=28842251; DOI=10.1016/j.bbrc.2017.08.081;
RA   Ianni A., Hoelper S., Krueger M., Braun T., Bober E.;
RT   "Sirt7 stabilizes rDNA heterochromatin through recruitment of DNMT1 and
RT   Sirt1.";
RL   Biochem. Biophys. Res. Commun. 492:434-440(2017).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 731-1602 IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE AND DNA, AND AUTOINHIBITORY LINKER.
RX   PubMed=21163962; DOI=10.1126/science.1195380;
RA   Song J., Rechkoblit O., Bestor T.H., Patel D.J.;
RT   "Structure of DNMT1-DNA complex reveals a role for autoinhibition in
RT   maintenance DNA methylation.";
RL   Science 331:1036-1040(2011).
CC   -!- FUNCTION: Methylates CpG residues. Preferentially methylates
CC       hemimethylated DNA. Associates with DNA replication sites in S phase
CC       maintaining the methylation pattern in the newly synthesized strand,
CC       that is essential for epigenetic inheritance. Associates with chromatin
CC       during G2 and M phases to maintain DNA methylation independently of
CC       replication. It is responsible for maintaining methylation patterns
CC       established in development. DNA methylation is coordinated with
CC       methylation of histones. Mediates transcriptional repression by direct
CC       binding to HDAC2. In association with DNMT3B and via the recruitment of
CC       CTCFL/BORIS, involved in activation of BAG1 gene expression by
CC       modulating dimethylation of promoter histone H3 at H3K4 and H3K9.
CC       Probably forms a corepressor complex required for activated KRAS-
CC       mediated promoter hypermethylation and transcriptional silencing of
CC       tumor suppressor genes (TSGs) or other tumor-related genes in
CC       colorectal cancer (CRC) cells (By similarity). Also required to
CC       maintain a transcriptionally repressive state of genes in
CC       undifferentiated embryonic stem cells (ESCs) (By similarity).
CC       Associates at promoter regions of tumor suppressor genes (TSGs) leading
CC       to their gene silencing (By similarity). Promotes tumor growth (By
CC       similarity). {ECO:0000250|UniProtKB:P26358,
CC       ECO:0000269|PubMed:11290321, ECO:0000269|PubMed:15550930,
CC       ECO:0000269|PubMed:17576694}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxycytidine in DNA + S-adenosyl-L-methionine = a 5-
CC         methyl-2'-deoxycytidine in DNA + S-adenosyl-L-homocysteine + H(+);
CC         Xref=Rhea:RHEA:13681, Rhea:RHEA-COMP:11369, Rhea:RHEA-COMP:11370,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57856, ChEBI:CHEBI:59789,
CC         ChEBI:CHEBI:85452, ChEBI:CHEBI:85454; EC=2.1.1.37;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10018};
CC   -!- ACTIVITY REGULATION: Allosterically regulated. The binding of 5-
CC       methylcytosine-containing DNA to the N-terminal parts of DNMT1 causes
CC       an allosteric activation of the catalytic domain by a direct
CC       interaction of its Zn-binding domain with the catalytic domain.
CC       {ECO:0000269|PubMed:1628623}.
CC   -!- SUBUNIT: Homodimer (By similarity). Forms a stable complex with E2F1,
CC       BB1 and HDAC1 (By similarity). Forms a complex with DMAP1 and HDAC2,
CC       with direct interaction (PubMed:10888872). Interacts with the PRC2/EED-
CC       EZH2 complex (PubMed:16357870). Probably part of a corepressor complex
CC       containing ZNF304, TRIM28, SETDB1 and DNMT1 (By similarity). Interacts
CC       with UHRF1; promoting its recruitment to hemimethylated DNA
CC       (PubMed:21268065). Interacts with USP7, promoting its deubiquitination
CC       (PubMed:21268065). Interacts with BAZ2A/TIP5 (PubMed:16085498).
CC       Interacts with PCNA (By similarity). Interacts with MBD2 and MBD3 (By
CC       similarity). Interacts with DNMT3A and DNMT3B (By similarity).
CC       Interacts with UBC9 (By similarity). Interacts with HDAC1
CC       (PubMed:10615135). Interacts with CSNK1D (PubMed:20192920). Interacts
CC       with SIRT7 (PubMed:28842251). Interacts with ZNF263; recruited to the
CC       SIX3 promoter along with other proteins involved in chromatin
CC       modification and transcriptional corepression where it contributes to
CC       transcriptional repression (By similarity). Interacts with L3MBTL3 and
CC       DCAF5; the interaction requires DNMT1 methylation at Lys-139 and is
CC       necessary to target DNMT1 for ubiquitination by the CRL4-DCAF5 E3
CC       ubiquitin ligase complex and proteasomal degradation (By similarity).
CC       Interacts with PHF20L1; the interaction requires DNMT1 methylation at
CC       Lys-139 and protects DNMT1 from ubiquitination and proteasomal
CC       degradation (By similarity). {ECO:0000250|UniProtKB:P26358,
CC       ECO:0000269|PubMed:10615135, ECO:0000269|PubMed:10888872,
CC       ECO:0000269|PubMed:16085498, ECO:0000269|PubMed:16357870,
CC       ECO:0000269|PubMed:20192920, ECO:0000269|PubMed:21268065,
CC       ECO:0000269|PubMed:28842251}.
CC   -!- INTERACTION:
CC       P13864; O09106: Hdac1; NbExp=3; IntAct=EBI-301927, EBI-301912;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11290321}. Cytoplasm
CC       {ECO:0000269|PubMed:11290321}. Note=It is nucleoplasmic through most of
CC       the cell cycle and associates with replication foci during S-phase. In
CC       germ cells, spermatogonia, preleptotene and leptotene spermatocytes all
CC       express high levels of nuclear protein, while the protein is not
CC       detected in pachytene spermatocytes, despite the fact they expressed
CC       high levels of mRNA. In females, the protein is not detected in non-
CC       growing oocytes, in contrast to the growing oocytes. During the
CC       growing, the protein is no longer detectable in nuclei but accumulates
CC       to very high levels first throughout the cytoplasm. At the time of
CC       ovulation, all the protein is cytoplasmic and is actively associated
CC       with the oocyte cortex. After fecondation, in the preimplantation
CC       embryo, the protein remains cytoplasmic and after implantation, it is
CC       exclusively nuclear in all tissue types. Isoform 2 is sequestered in
CC       the cytoplasm of maturing oocytes and of preimplantation embryos,
CC       except for the 8-cell stage, while isoform 1 is exclusively nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long;
CC         IsoId=P13864-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P13864-2; Sequence=VSP_005619;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in embryonic stem cells and
CC       in somatic tissues. Isoform 2 is expressed in oocytes, preimplantation
CC       embryos, testis and in skeletal muscle during myogenesis.
CC   -!- DEVELOPMENTAL STAGE: In germ cells, it is present at high levels in
CC       spermatogonia and spermatocytes until the pachytene stage, where it
CC       falls to undetectable levels. The transient drop at the pachytene stage
CC       coincides with the disappearance of the 5.2 kb mRNA and the
CC       accumulation of a larger 6.0 kb mRNA. Oocytes accumulate very large
CC       amounts of Dnmt1 protein during the growth phase.
CC   -!- DOMAIN: The N-terminal part is required for homodimerization and acts
CC       as a regulatory domain.
CC   -!- DOMAIN: The CXXC-type zinc finger specifically binds to unmethylated
CC       CpG dinucleotides, positioning the autoinhibitory linker between the
CC       DNA and the active site, thus providing a mechanism to ensure that only
CC       hemimethylated CpG dinucleotides undergo methylation.
CC       {ECO:0000269|PubMed:21163962}.
CC   -!- PTM: Sumoylated; sumoylation increases activity.
CC       {ECO:0000250|UniProtKB:P26358}.
CC   -!- PTM: Phosphorylation at Ser-146 by CK1 reduces DNA-binding activity.
CC       {ECO:0000269|PubMed:17965600, ECO:0000269|PubMed:20192920,
CC       ECO:0000269|PubMed:9211941}.
CC   -!- PTM: Acetylation on multiple lysines, mainly by KAT2B/PCAF, regulates
CC       cell cycle G(2)/M transition. Deacetylation of Lys-1352 and Lys-1418 by
CC       SIRT1 increases methyltransferase activity.
CC       {ECO:0000250|UniProtKB:P26358}.
CC   -!- PTM: Phosphorylation of Ser-152 by CDKs is important for enzymatic
CC       activity and protein stability. Phosphorylation of Ser-140 by AKT1
CC       prevents methylation by SETD7 thereby increasing DNMT1 stability.
CC       {ECO:0000250|UniProtKB:P26358}.
CC   -!- PTM: Methylation at Lys-139 by SETD7 is necessary for the regulation of
CC       DNMT1 proteasomal degradation. {ECO:0000250|UniProtKB:P26358}.
CC   -!- PTM: Ubiquitinated by UHRF1; interaction with USP7 counteracts
CC       ubiquitination by UHRF1 by promoting deubiquitination and preventing
CC       degradation by the proteasome. {ECO:0000269|PubMed:21268065}.
CC   -!- MISCELLANEOUS: There are three 5' exons, one specific to the oocyte
CC       (1c), one specific to the pachytene spermatocyte and also found in
CC       skeletal muscle (1b) and one found in somatic cells (1a). Three
CC       different mRNAs can be produced which give rise to two different
CC       translation products: isoform 1 (mRNAs-1a) and isoform 2 (mRNA-1b or
CC       -1c). Association of DNMT1 with the replication machinery is not
CC       strictly required for maintaining global methylation but still enhances
CC       methylation efficiency by 2-fold. Pre-existing cytosine methylation at
CC       CpG and non-CpG sites enhances methylation activity.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding methyltransferase
CC       superfamily. C5-methyltransferase family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01016}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC52900.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X14805; CAA32910.1; -; mRNA.
DR   EMBL; AF175432; AAF97695.1; -; mRNA.
DR   EMBL; AF162282; AAF19352.1; -; mRNA.
DR   EMBL; AF175431; AAF60965.1; -; Genomic_DNA.
DR   EMBL; AF175412; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175413; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175414; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF244089; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF244090; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175416; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175417; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175418; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175419; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175420; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175421; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175422; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175423; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF234317; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175424; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175425; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175426; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF234318; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175427; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175428; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175429; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; AF175430; AAF60965.1; JOINED; Genomic_DNA.
DR   EMBL; BC048148; AAH48148.2; -; mRNA.
DR   EMBL; AF036007; AAC40061.1; -; mRNA.
DR   EMBL; AF036008; AAC53551.1; -; Genomic_DNA.
DR   EMBL; U70051; AAC52900.1; ALT_INIT; mRNA.
DR   EMBL; AK013247; BAB28743.1; -; mRNA.
DR   CCDS; CCDS57654.1; -. [P13864-2]
DR   CCDS; CCDS57655.1; -. [P13864-1]
DR   PIR; S01845; S01845.
DR   RefSeq; NP_001186360.2; NM_001199431.2. [P13864-1]
DR   RefSeq; NP_001186361.1; NM_001199432.1.
DR   RefSeq; NP_001186362.1; NM_001199433.2. [P13864-2]
DR   RefSeq; NP_001300940.1; NM_001314011.1.
DR   RefSeq; NP_034196.5; NM_010066.4.
DR   PDB; 3AV4; X-ray; 2.75 A; A=291-1620.
DR   PDB; 3AV5; X-ray; 3.25 A; A=291-1620.
DR   PDB; 3AV6; X-ray; 3.09 A; A=291-1620.
DR   PDB; 3PT6; X-ray; 3.00 A; A/B=650-1602.
DR   PDB; 3PT9; X-ray; 2.50 A; A=731-1602.
DR   PDB; 4DA4; X-ray; 2.60 A; A/B=731-1602.
DR   PDB; 5GUT; X-ray; 2.10 A; A=731-1602.
DR   PDB; 5GUV; X-ray; 3.08 A; A=731-1602.
DR   PDB; 5WY1; X-ray; 3.27 A; A=291-1620.
DR   PDB; 6W8V; X-ray; 3.12 A; A/B=731-1602.
DR   PDB; 6W8W; X-ray; 3.00 A; A/B=731-1602.
DR   PDBsum; 3AV4; -.
DR   PDBsum; 3AV5; -.
DR   PDBsum; 3AV6; -.
DR   PDBsum; 3PT6; -.
DR   PDBsum; 3PT9; -.
DR   PDBsum; 4DA4; -.
DR   PDBsum; 5GUT; -.
DR   PDBsum; 5GUV; -.
DR   PDBsum; 5WY1; -.
DR   PDBsum; 6W8V; -.
DR   PDBsum; 6W8W; -.
DR   AlphaFoldDB; P13864; -.
DR   SMR; P13864; -.
DR   BioGRID; 199259; 39.
DR   CORUM; P13864; -.
DR   FunCoup; P13864; 2377.
DR   IntAct; P13864; 12.
DR   MINT; P13864; -.
DR   STRING; 10090.ENSMUSP00000004202; -.
DR   BindingDB; P13864; -.
DR   ChEMBL; CHEMBL3351195; -.
DR   REBASE; 2844; M.MmuDnmt1.
DR   GlyGen; P13864; 4 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (2 sites).
DR   iPTMnet; P13864; -.
DR   PhosphoSitePlus; P13864; -.
DR   SwissPalm; P13864; -.
DR   jPOST; P13864; -.
DR   PaxDb; 10090-ENSMUSP00000004202; -.
DR   PeptideAtlas; P13864; -.
DR   ProteomicsDB; 277482; -. [P13864-1]
DR   ProteomicsDB; 277483; -. [P13864-2]
DR   Pumba; P13864; -.
DR   Antibodypedia; 1052; 1564 antibodies from 50 providers.
DR   DNASU; 13433; -.
DR   Ensembl; ENSMUST00000004202.17; ENSMUSP00000004202.10; ENSMUSG00000004099.17. [P13864-1]
DR   Ensembl; ENSMUST00000216540.2; ENSMUSP00000150433.2; ENSMUSG00000004099.17. [P13864-2]
DR   GeneID; 13433; -.
DR   KEGG; mmu:13433; -.
DR   UCSC; uc009ojo.2; mouse. [P13864-1]
DR   AGR; MGI:94912; -.
DR   CTD; 1786; -.
DR   MGI; MGI:94912; Dnmt1.
DR   VEuPathDB; HostDB:ENSMUSG00000004099; -.
DR   eggNOG; ENOG502QPKK; Eukaryota.
DR   GeneTree; ENSGT00390000005100; -.
DR   InParanoid; P13864; -.
DR   OMA; CKEMAPL; -.
DR   OrthoDB; 5376140at2759; -.
DR   PhylomeDB; P13864; -.
DR   BRENDA; 2.1.1.37; 3474.
DR   Reactome; R-MMU-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-MMU-4655427; SUMOylation of DNA methylation proteins.
DR   BioGRID-ORCS; 13433; 14 hits in 82 CRISPR screens.
DR   ChiTaRS; Dnmt1; mouse.
DR   EvolutionaryTrace; P13864; -.
DR   PRO; PR:P13864; -.
DR   Proteomes; UP000000589; Chromosome 9.
DR   RNAct; P13864; protein.
DR   Bgee; ENSMUSG00000004099; Expressed in floor plate of midbrain and 318 other cell types or tissues.
DR   ExpressionAtlas; P13864; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0001674; C:female germ cell nucleus; IDA:MGI.
DR   GO; GO:0043073; C:germ cell nucleus; IDA:MGI.
DR   GO; GO:0000792; C:heterochromatin; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005721; C:pericentric heterochromatin; IDA:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IDA:MGI.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0003886; F:DNA (cytosine-5-)-methyltransferase activity; IDA:MGI.
DR   GO; GO:0051718; F:DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0009008; F:DNA-methyltransferase activity; IMP:MGI.
DR   GO; GO:0106222; F:lncRNA binding; IDA:MGI.
DR   GO; GO:0008327; F:methyl-CpG binding; IDA:MGI.
DR   GO; GO:0008168; F:methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; ISS:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:MGI.
DR   GO; GO:0008270; F:zinc ion binding; IDA:MGI.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:MGI.
DR   GO; GO:1903926; P:cellular response to bisphenol A; IDA:MGI.
DR   GO; GO:0141119; P:chromosomal DNA methylation maintenance following DNA replication; IDA:MGI.
DR   GO; GO:0006346; P:DNA methylation-dependent constitutive heterochromatin formation; IDA:UniProtKB.
DR   GO; GO:0006351; P:DNA-templated transcription; IMP:MGI.
DR   GO; GO:0043045; P:epigenetic programming of gene expression; IMP:MGI.
DR   GO; GO:0032259; P:methylation; IEA:UniProtKB-KW.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:MGI.
DR   GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:1905460; P:negative regulation of vascular associated smooth muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:1905931; P:negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IGI:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   CDD; cd04760; BAH_Dnmt1_I; 1.
DR   CDD; cd04711; BAH_Dnmt1_II; 1.
DR   FunFam; 1.10.10.2230:FF:000001; DNA (cytosine-5)-methyltransferase; 1.
DR   FunFam; 2.30.30.490:FF:000004; DNA (cytosine-5)-methyltransferase; 1.
DR   FunFam; 3.40.50.150:FF:000036; DNA (cytosine-5)-methyltransferase; 1.
DR   FunFam; 3.40.50.150:FF:000108; DNA (cytosine-5)-methyltransferase; 1.
DR   FunFam; 3.90.120.10:FF:000001; DNA (cytosine-5)-methyltransferase; 1.
DR   Gene3D; 1.10.10.2230; -; 1.
DR   Gene3D; 2.30.30.490; -; 2.
DR   Gene3D; 3.90.120.10; DNA Methylase, subunit A, domain 2; 1.
DR   Gene3D; 3.40.50.150; Vaccinia Virus protein VP39; 1.
DR   InterPro; IPR001025; BAH_dom.
DR   InterPro; IPR043151; BAH_sf.
DR   InterPro; IPR050390; C5-Methyltransferase.
DR   InterPro; IPR018117; C5_DNA_meth_AS.
DR   InterPro; IPR001525; C5_MeTfrase.
DR   InterPro; IPR031303; C5_meth_CS.
DR   InterPro; IPR022702; Cytosine_MeTrfase1_RFD.
DR   InterPro; IPR010506; DMAP1-bd.
DR   InterPro; IPR017198; DNMT1-like.
DR   InterPro; IPR029063; SAM-dependent_MTases_sf.
DR   InterPro; IPR002857; Znf_CXXC.
DR   PANTHER; PTHR10629; CYTOSINE-SPECIFIC METHYLTRANSFERASE; 1.
DR   PANTHER; PTHR10629:SF52; DNA (CYTOSINE-5)-METHYLTRANSFERASE 1; 1.
DR   Pfam; PF01426; BAH; 2.
DR   Pfam; PF06464; DMAP_binding; 1.
DR   Pfam; PF00145; DNA_methylase; 1.
DR   Pfam; PF12047; DNMT1-RFD; 1.
DR   Pfam; PF02008; zf-CXXC; 1.
DR   PIRSF; PIRSF037404; DNMT1; 1.
DR   PRINTS; PR00105; C5METTRFRASE.
DR   SMART; SM00439; BAH; 2.
DR   SMART; SM01137; DMAP_binding; 1.
DR   SUPFAM; SSF53335; S-adenosyl-L-methionine-dependent methyltransferases; 1.
DR   PROSITE; PS51038; BAH; 2.
DR   PROSITE; PS00094; C5_MTASE_1; 1.
DR   PROSITE; PS00095; C5_MTASE_2; 1.
DR   PROSITE; PS51912; DMAP1_BIND; 1.
DR   PROSITE; PS51679; SAM_MT_C5; 1.
DR   PROSITE; PS51058; ZF_CXXC; 1.
DR   TreeFam; TF328926; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Allosteric enzyme;
KW   Alternative splicing; Chromatin regulator; Cytoplasm;
KW   Direct protein sequencing; DNA-binding; Isopeptide bond; Metal-binding;
KW   Methylation; Methyltransferase; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; S-adenosyl-L-methionine;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   CHAIN           1..1620
FT                   /note="DNA (cytosine-5)-methyltransferase 1"
FT                   /id="PRO_0000088035"
FT   DOMAIN          16..109
FT                   /note="DMAP1-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01260"
FT   DOMAIN          758..884
FT                   /note="BAH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00370"
FT   DOMAIN          976..1103
FT                   /note="BAH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00370"
FT   REPEAT          1112..1113
FT                   /note="1"
FT   REPEAT          1114..1115
FT                   /note="2"
FT   REPEAT          1116..1117
FT                   /note="3"
FT   REPEAT          1118..1119
FT                   /note="4"
FT   REPEAT          1120..1121
FT                   /note="5"
FT   REPEAT          1122..1123
FT                   /note="6"
FT   REPEAT          1124..1125
FT                   /note="7; approximate"
FT   DOMAIN          1142..1601
FT                   /note="SAM-dependent MTase C5-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01016"
FT   ZN_FING         649..695
FT                   /note="CXXC-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   REGION          1..343
FT                   /note="Interaction with the PRC2/EED-EZH2 complex"
FT   REGION          1..145
FT                   /note="Interaction with DNMT3A"
FT                   /evidence="ECO:0000250"
FT   REGION          1..120
FT                   /note="Interaction with DMAP1"
FT                   /evidence="ECO:0000269|PubMed:10888872"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          96..369
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          147..217
FT                   /note="Interaction with DNMT3B"
FT                   /evidence="ECO:0000250"
FT   REGION          161..172
FT                   /note="Interaction with PCNA"
FT   REGION          305..609
FT                   /note="Interaction with the PRC2/EED-EZH2 complex"
FT   REGION          328..556
FT                   /note="DNA replication foci-targeting sequence"
FT                   /evidence="ECO:0000250"
FT   REGION          696..813
FT                   /note="Interaction with HDAC1"
FT                   /evidence="ECO:0000269|PubMed:10615135"
FT   REGION          696..757
FT                   /note="Autoinhibitory linker"
FT   REGION          702..732
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1097..1136
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1112..1125
FT                   /note="7 X 2 AA tandem repeats of K-G"
FT   REGION          1124..1620
FT                   /note="Interaction with the PRC2/EED-EZH2 complex"
FT   REGION          1142..1620
FT                   /note="Catalytic"
FT   MOTIF           175..202
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        126..137
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        144..155
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        192..205
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        246..267
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        286..300
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        308..317
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        702..713
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        719..730
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1113..1125
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1126..1135
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1229
FT                   /evidence="ECO:0000269|PubMed:17576694"
FT   BINDING         359
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         362
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         420
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         424
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         656
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         659
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         662
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         667
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         670
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         673
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         689
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         694
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00509"
FT   BINDING         1149
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:21163962,
FT                   ECO:0007744|PDB:3PT6, ECO:0007744|PDB:4DA4"
FT   BINDING         1153..1154
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:21163962,
FT                   ECO:0007744|PDB:3PT6, ECO:0007744|PDB:3PT9,
FT                   ECO:0007744|PDB:4DA4"
FT   BINDING         1171..1172
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:21163962,
FT                   ECO:0007744|PDB:3PT6, ECO:0007744|PDB:3PT9,
FT                   ECO:0007744|PDB:4DA4"
FT   BINDING         1193..1194
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:21163962,
FT                   ECO:0007744|PDB:3PT6, ECO:0007744|PDB:3PT9"
FT   BINDING         1582
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:21163962,
FT                   ECO:0007744|PDB:3PT6, ECO:0007744|PDB:3PT9,
FT                   ECO:0007744|PDB:4DA4"
FT   MOD_RES         15
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         70
FT                   /note="N6,N6-dimethyllysine; by EHMT2"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         138
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         139
FT                   /note="N6-methyllysine; by SETD7"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         146
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:20192920,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         150
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         164
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         171
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         240
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         255
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         372
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         515
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17965600,
FT                   ECO:0000269|PubMed:9211941"
FT   MOD_RES         555
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         713
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         717
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:19144319, ECO:0007744|PubMed:21183079"
FT   MOD_RES         735
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         752
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         882
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         895
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         961
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         965
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         979
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         1114
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         1116
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         1118
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         1120
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         1122
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:23806337"
FT   MOD_RES         1124
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:23806337"
FT   MOD_RES         1352
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   MOD_RES         1418
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   CROSSLNK        255
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   CROSSLNK        1611
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P26358"
FT   VAR_SEQ         1..118
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10715201,
FT                   ECO:0000303|PubMed:11063128, ECO:0000303|PubMed:9449671"
FT                   /id="VSP_005619"
FT   MUTAGEN         162
FT                   /note="Q->E: Abolishes interaction with PCNA. No effect on
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17576694"
FT   MUTAGEN         169
FT                   /note="F->S: Abolishes interaction with PCNA. No effect on
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17576694"
FT   MUTAGEN         515
FT                   /note="S->A: Loss of activity. No effect on DNA-binding
FT                   capacity."
FT                   /evidence="ECO:0000269|PubMed:17965600"
FT   MUTAGEN         515
FT                   /note="S->E: Slightly reduces activity."
FT                   /evidence="ECO:0000269|PubMed:17965600"
FT   MUTAGEN         1229
FT                   /note="C->W: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:17576694"
FT   CONFLICT        146..147
FT                   /note="SV -> F (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        299..309
FT                   /note="AEPEQVAPETP -> VRARAGSSRDS (in Ref. 1; CAA32910 and
FT                   6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        936
FT                   /note="V -> C (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        947
FT                   /note="P -> R (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        969..976
FT                   /note="NETLYPEH -> KENPVPRDT (in Ref. 1; CAA32910 and 6;
FT                   AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        987
FT                   /note="S -> R (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1046
FT                   /note="Y -> C (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1068
FT                   /note="G -> R (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1429
FT                   /note="R -> P (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1456
FT                   /note="H -> D (in Ref. 1; CAA32910 and 6; AAC40061)"
FT                   /evidence="ECO:0000305"
FT   TURN            360..362
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          365..367
FT                   /evidence="ECO:0007829|PDB:5WY1"
FT   HELIX           383..387
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          406..408
FT                   /evidence="ECO:0007829|PDB:3AV5"
FT   STRAND          410..419
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          423..425
FT                   /evidence="ECO:0007829|PDB:3AV6"
FT   TURN            432..436
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          440..445
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          454..458
FT                   /evidence="ECO:0007829|PDB:3AV6"
FT   STRAND          459..465
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          469..473
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          475..479
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          482..486
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          491..494
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   TURN            499..501
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           502..524
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           530..539
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           553..558
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           560..573
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           581..583
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           585..593
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           625..635
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          657..659
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   TURN            660..663
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   TURN            671..675
FT                   /evidence="ECO:0007829|PDB:3PT6"
FT   TURN            677..680
FT                   /evidence="ECO:0007829|PDB:3PT6"
FT   HELIX           690..692
FT                   /evidence="ECO:0007829|PDB:3PT6"
FT   HELIX           695..704
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          734..739
FT                   /evidence="ECO:0007829|PDB:3PT9"
FT   STRAND          741..743
FT                   /evidence="ECO:0007829|PDB:3PT9"
FT   STRAND          745..751
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          753..755
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          758..760
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          765..768
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          774..776
FT                   /evidence="ECO:0007829|PDB:4DA4"
FT   STRAND          778..788
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          793..802
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           803..805
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          806..808
FT                   /evidence="ECO:0007829|PDB:6W8W"
FT   HELIX           809..811
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          816..827
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           828..830
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          831..835
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          837..839
FT                   /evidence="ECO:0007829|PDB:3PT9"
FT   HELIX           846..848
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          868..874
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            875..878
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          879..881
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            890..895
FT                   /evidence="ECO:0007829|PDB:3PT9"
FT   HELIX           898..910
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          913..920
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          922..924
FT                   /evidence="ECO:0007829|PDB:3AV5"
FT   STRAND          925..932
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          935..938
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          942..945
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           947..949
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            970..972
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           976..979
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          996..1008
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1011..1023
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1027..1029
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1031..1036
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1037..1039
FT                   /evidence="ECO:0007829|PDB:3PT6"
FT   STRAND          1044..1047
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1051..1055
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1056..1058
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1061..1067
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1068..1070
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1075..1081
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1085..1091
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1094..1096
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1098..1100
FT                   /evidence="ECO:0007829|PDB:4DA4"
FT   HELIX           1104..1106
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1142..1147
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1153..1161
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1163..1170
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1174..1183
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1187..1190
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1194..1202
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1217..1219
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1221..1225
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1230..1232
FT                   /evidence="ECO:0007829|PDB:4DA4"
FT   STRAND          1234..1236
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   HELIX           1240..1247
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1250..1261
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1264..1271
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1272..1275
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1277..1293
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1296..1303
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1304..1307
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1314..1321
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1339..1341
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1346..1348
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1351..1353
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1370..1374
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1375..1377
FT                   /evidence="ECO:0007829|PDB:3PT6"
FT   STRAND          1387..1390
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1398..1404
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1411..1413
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1422..1429
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1433..1436
FT                   /evidence="ECO:0007829|PDB:3AV5"
FT   HELIX           1439..1441
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1450..1452
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1454..1456
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1465..1467
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1477..1479
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1480..1483
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1489..1491
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          1495..1498
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1501..1505
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1506..1512
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1513..1516
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1525..1527
FT                   /evidence="ECO:0007829|PDB:3AV4"
FT   STRAND          1536..1538
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   STRAND          1544..1549
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1552..1558
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1571..1580
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   HELIX           1584..1596
FT                   /evidence="ECO:0007829|PDB:5GUT"
FT   TURN            1607..1611
FT                   /evidence="ECO:0007829|PDB:5WY1"
SQ   SEQUENCE   1620 AA;  183189 MW;  4F9A98CEAF09F037 CRC64;
     MPARTAPARV PALASPAGSL PDHVRRRLKD LERDGLTEKE CVREKLNLLH EFLQTEIKSQ
     LCDLETKLHK EELSEEGYLA KVKSLLNKDL SLENGTHTLT QKANGCPANG SRPTWRAEMA
     DSNRSPRSRP KPRGPRRSKS DSDTLSVETS PSSVATRRTT RQTTITAHFT KGPTKRKPKE
     ESEEGNSAES AAEERDQDKK RRVVDTESGA AAAVEKLEEV TAGTQLGPEE PCEQEDDNRS
     LRRHTRELSL RRKSKEDPDR EARPETHLDE DEDGKKDKRS SRPRSQPRDP AAKRRPKEAE
     PEQVAPETPE DRDEDEREEK RRKTTRKKLE SHTVPVQSRS ERKAAQSKSV IPKINSPKCP
     ECGQHLDDPN LKYQQHPEDA VDEPQMLTSE KLSIYDSTST WFDTYEDSPM HRFTSFSVYC
     SRGHLCPVDT GLIEKNVELY FSGCAKAIHD ENPSMEGGIN GKNLGPINQW WLSGFDGGEK
     VLIGFSTAFA EYILMEPSKE YEPIFGLMQE KIYISKIVVE FLQNNPDAVY EDLINKIETT
     VPPSTINVNR FTEDSLLRHA QFVVSQVESY DEAKDDDETP IFLSPCMRAL IHLAGVSLGQ
     RRATRRVMGA TKEKDKAPTK ATTTKLVYQI FDTFFSEQIE KYDKEDKENA MKRRRCGVCE
     VCQQPECGKC KACKDMVKFG GTGRSKQACL KRRCPNLAVK EADDDEEADD DVSEMPSPKK
     LHQGKKKKQN KDRISWLGQP MKIEENRTYY QKVSIDEEML EVGDCVSVIP DDSSKPLYLA
     RVTALWEDKN GQMMFHAHWF CAGTDTVLGA TSDPLELFLV GECENMQLSY IHSKVKVIYK
     APSENWAMEG GTDPETTLPG AEDGKTYFFQ LWYNQEYARF ESPPKTQPTE DNKHKFCLSC
     IRLAELRQKE MPKVLEQIEE VDGRVYCSSI TKNGVVYRLG DSVYLPPEAF TFNIKVASPV
     KRPKKDPVNE TLYPEHYRKY SDYIKGSNLD APEPYRIGRI KEIHCGKKKG KVNEADIKLR
     LYKFYRPENT HRSYNGSYHT DINMLYWSDE EAVVNFSDVQ GRCTVEYGED LLESIQDYSQ
     GGPDRFYFLE AYNSKTKNFE DPPNHARSPG NKGKGKGKGK GKGKHQVSEP KEPEAAIKLP
     KLRTLDVFSG CGGLSEGFHQ AGISETLWAI EMWDPAAQAF RLNNPGTTVF TEDCNVLLKL
     VMAGEVTNSL GQRLPQKGDV EMLCGGPPCQ GFSGMNRFNS RTYSKFKNSL VVSFLSYCDY
     YRPRFFLLEN VRNFVSYRRS MVLKLTLRCL VRMGYQCTFG VLQAGQYGVA QTRRRAIILA
     AAPGEKLPLF PEPLHVFAPR ACQLSVVVDD KKFVSNITRL SSGPFRTITV RDTMSDLPEI
     QNGASNSEIP YNGEPLSWFQ RQLRGSHYQP ILRDHICKDM SPLVAARMRH IPLFPGSDWR
     DLPNIQVRLG DGVIAHKLQY TFHDVKNGYS STGALRGVCS CAEGKACDPE SRQFSTLIPW
     CLPHTGNRHN HWAGLYGRLE WDGFFSTTVT NPEPMGKQGR VLHPEQHRVV SVRECARSQG
     FPDSYRFFGN ILDRHRQVGN AVPPPLAKAI GLEIKLCLLS SARESASAAV KAKEEAATKD
//
